Adenosine Shapes Neonatal Toll-like Receptor Function
腺苷塑造新生儿 Toll 样受体功能
基本信息
- 批准号:7140003
- 负责人:
- 金额:$ 38.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Newborns are at increased risk of infection yet the mechanisms underlying their susceptibility are incompletely defined. Toll-like receptors (TLRs) play crucial roles in the recognition of microbial components including bacterial lipopeptides (BLPs), expressed by a wide-range of bacteria, that activate monocytes via a heterodimer of TLR1/2 (triacylated BLPs) or TLR2/6 (diacylated BLPs). Preliminary studies indicate that despite normal expression of TLRs and associated signaling components, human newborn blood monocytes demonstrate a 2- to 3-log impairment in BLP-induced synthesis of pro-inflammatory and Th1-polarizing cytokine tumor necrosis factor-alpha (TNF-alpha) with preservation of BLP-induced production of IL-6, a cytokine with anti-inflammatory and Th2-polarizing activities. Similar impairment in neonatal TNF-alpha production is evident in response to E. coli K1/r, a pathogenic bacterium that expresses BLPs. We have discovered that impaired BLP- and E. col1- induced TNF-alpha production from neonatal blood monocytes is attributable to the action of plasma adenosine, an endogenous purine metabolite with immunomodulatory properties that is released from cells under conditions of stress or hypoxia. Neonatal mononuclear cells are especially sensitive to adenosine-induced inhibition of TNF-alpha production and to adenosine-induced production of cyclic AMP, an intracellular metabolite that inhibits TNF-alpha synthesis while preserving IL-6 production. The overall goal of this project is to characterize the role of the neonatal adenosine system in modulating TLR-mediated innate immune responses in neonatal blood monocytes. This goal will be accomplished through three specific aims: (1) to determine the mechanism for the greater adenosine sensitivity of neonatal mononuclear cells, (2) to define the adenosine receptor sub-type(s) that mediate inhibition of BLP- and E. coli-induced TNF-alpha production from neonatal blood monocytes; and (3) to characterize the mechanism by which engagement of adenosine receptors results in diminished BLP- and E. coli-induced monocyte TNF-alpha production while preserving IL-6 production. Mechanistic analysis will define how adenosine alters neonatal TLR-mediated immune responses. As a whole, these studies will deepen our understanding of how the unique physiology of the human newborn fundamentally alters innate immunity at birth.
描述(由申请人提供):新生儿感染的风险增加,但其易感性的机制尚未完全确定。Toll样受体(Toll-like Receptor,TLRs)在识别微生物成分中起着至关重要的作用,包括细菌脂肽(BLPs),它们通过TLR1/2(三酰化BLPs)或TLR2/6(二酰化BLPs)的异源二聚体激活单核细胞,在多种细菌中表达。初步研究表明,尽管TLRs及其相关信号成分表达正常,但在BLP诱导的促炎和Th1极化细胞因子肿瘤坏死因子-α(TNF-α)的合成过程中,人类新生儿单核细胞表现出2-3对数的损伤,但保留了BLP诱导的IL-6的产生,IL-6具有抗炎和Th2极化活性。对表达BLPS的致病细菌E.ColiK1/r的反应中,新生儿肿瘤坏死因子-α的产生也明显受到类似的损害。我们发现,BLP和E.col1诱导的新生儿单核细胞产生的肿瘤坏死因子-α的减少是由于血浆腺苷的作用,腺苷是一种内源性嘌呤代谢产物,具有免疫调节特性,在应激或缺氧条件下从细胞中释放出来。新生儿单个核细胞对腺苷诱导的肿瘤坏死因子-α的产生抑制和腺苷诱导的环磷酸腺苷的产生特别敏感,环磷酸腺苷是一种细胞内代谢物,可以抑制肿瘤坏死因子-α的合成,同时保持IL-6的产生。该项目的总体目标是表征新生儿腺苷系统在调节TLR介导的新生儿单核细胞天然免疫反应中的作用。这一目标将通过三个具体目标来实现:(1)确定新生儿单核细胞对腺苷更敏感的机制,(2)确定腺苷受体亚型(S),该亚型介导抑制BLP和大肠杆菌诱导的新生儿单核细胞产生肿瘤坏死因子-α,以及(3)表征腺苷受体结合导致BLP和E.Coli诱导的单核细胞产生减少的肿瘤坏死因子-α,同时保持IL-6产生的机制。机制分析将定义腺苷如何改变新生儿TLR介导的免疫反应。总体而言,这些研究将加深我们对人类新生儿独特的生理如何从根本上改变出生时的先天免疫的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OFER LEVY其他文献
OFER LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OFER LEVY', 18)}}的其他基金
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10435035 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10435043 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10589800 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10435036 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10589801 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10290547 - 财政年份:2021
- 资助金额:
$ 38.03万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10205742 - 财政年份:2021
- 资助金额:
$ 38.03万 - 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
- 批准号:
10323182 - 财政年份:2020
- 资助金额:
$ 38.03万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10221106 - 财政年份:2020
- 资助金额:
$ 38.03万 - 项目类别:
相似国自然基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
- 批准号:82371144
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
- 批准号:82371317
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
骨骼肌中胰高血糖素受体的表达及其调控血糖稳态的作用与机制研究
- 批准号:82370820
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
- 批准号:82371465
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
气体信号分子硫化氢对颈动脉窦压力反射感受器的调节作用及机制
- 批准号:81100181
- 批准年份:2011
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
精神分裂症特异微小RNA的筛选、鉴定及其靶向调控功能研究
- 批准号:81000583
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
人脐血间充质干细胞成骨潜能亚群的特异性分子标志
- 批准号:30800232
- 批准年份:2008
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 38.03万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 38.03万 - 项目类别:
Multiplexed enzyme-linked immunosorbent assay workstation for clinical research
用于临床研究的多重酶联免疫吸附测定工作站
- 批准号:
10413539 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Clinical Research Scholars Training (CREST) Program
临床研究学者培训(CREST)计划
- 批准号:
10643720 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Video repositories for clinical research: Overcoming barriers and testing utility
用于临床研究的视频存储库:克服障碍和测试实用性
- 批准号:
10674051 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Clinical Research Scholars Training (CREST) Program
临床研究学者培训(CREST)计划
- 批准号:
10541753 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
Video repositories for clinical research: Overcoming barriers and testing utility
用于临床研究的视频存储库:克服障碍和测试实用性
- 批准号:
10523823 - 财政年份:2022
- 资助金额:
$ 38.03万 - 项目类别:
CAUSE Clinical Research Center New York (CAUSE-CRC)
纽约 CAUSE 临床研究中心 (CAUSE-CRC)
- 批准号:
10211937 - 财政年份:2021
- 资助金额:
$ 38.03万 - 项目类别:
Deployable, Single-use Device for Single Cell Genomics in Clinical Research
用于临床研究中单细胞基因组学的可部署一次性设备
- 批准号:
10258377 - 财政年份:2021
- 资助金额:
$ 38.03万 - 项目类别:
CAUSE Clinical Research Center New York (CAUSE-CRC)
纽约 CAUSE 临床研究中心 (CAUSE-CRC)
- 批准号:
10595558 - 财政年份:2021
- 资助金额:
$ 38.03万 - 项目类别: